Numab Therapeutics, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, successfully closes CHF 100 million (approximately USD 110 million) in Series C financing Round.
The financing was co-led by new investors Novo Ventures, the ventures arm of Novo Holdings, and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.
Baker McKenzie handled all legal aspects of the transaction for Numab with a team led by partners Martin Frey (pictured) and Berthold Hummel, and senior associates, Ramon Tissafi, Matthias Trautmann and Julia Schieber.
Bader Gnehm & Partner assisted HBM Healthcare Investments and Novo Holdings in the negotiations and advised them on all Swiss legal matters with a team led by Oliver Gnehm (Partner , pictured left) and Olivier Bula (Partner), Victoria Marty (Associate), Thomas Gysin (Associate) and Fabiola Anthamatten (Associate).
Proceeds will support acceleration and expansion of the clinical development of Numab’s lead program NM21-1480 into multiple cancer indications, and the advancement of the company’s pipeline of multi-specific antibodies in oncology and inflammation, into clinical trials.